Cargando…
Successful use of methylprednisolone for treating severe COVID-19
Autores principales: | Liu, Jing, Zheng, Xiaobin, Huang, Yiying, Shan, Hong, Huang, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256545/ https://www.ncbi.nlm.nih.gov/pubmed/32479759 http://dx.doi.org/10.1016/j.jaci.2020.05.021 |
Ejemplares similares
-
Hypersensitivity in the lungs is responsible for acute respiratory failure in COVID‐19 patients: Case series of patients who received high‐dose/short‐term methylprednisolone
por: Chen, Meizhu, et al.
Publicado: (2021) -
Intravenous pulse methylprednisolone for the treatment of severe COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2023) -
Kinetics of Severity Biomarkers and Immunological Features of Methylprednisolone Therapy for Severe COVID-19 Patients
por: Fan, Qinghong, et al.
Publicado: (2022) -
Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases
por: Zhu, Hong-Ming, et al.
Publicado: (2020) -
Methylprednisolone pulse therapy: An alternative management of severe COVID-19
por: Sauñe, Patricia Merab, et al.
Publicado: (2020)